or Try an Advanced Search...

    Technical Analysis for ACRV - Acrivon Therapeutics, Inc.

    Grade Last Price % Change Price Change
    F 6.45 -0.77% -0.05
    ACRV closed up 1.88 percent on Wednesday, November 20, 2024, on 33 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical ACRV trend table...
    Date Alert Name Type % Chg
    Slingshot Bearish Bearish Swing Setup -0.77%
    Lower Bollinger Band Walk Weakness -0.77%
    Wide Bands Range Expansion -0.77%
    Lower Bollinger Band Touch Weakness -0.77%
    Oversold Stochastic Weakness -0.77%
    Lower Bollinger Band Walk Weakness 1.10%
    Wide Bands Range Expansion 1.10%
    Below Lower BB Weakness 1.10%
    Oversold Stochastic Weakness 1.10%
    MACD Bearish Centerline Cross Bearish 2.87%
    Older End-of-Day Signals for ACRV ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakdown 14 minutes ago
    Down 1% about 2 hours ago
    Lower Bollinger Band Support about 2 hours ago
    Rose Above Previous Day's High about 3 hours ago
    Up 2% about 3 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    ACRV Chart by TradingView
    Basic chart:

    Profile

    Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops precision oncology medicines. The company's lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1/2 for use in the treatment of platinum-resistant ovarian cancer; endometrial and bladder cancer; and SCCs, including SCCHN, cervical, and anal cancer. It is also developing two preclinical drug programs used to predict tumor sensitivity based on custom OncoSignature tests. The company was incorporated in 2018 and is based in Watertown, Massachusetts.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Cancer Oncology Tumor Ovarian Cancer Bladder Cancer Gynaecological Cancer Anal Cancer

    Is ACRV a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 13 Acrivon Therapeutics GAAP EPS of -$0.59
    Nov 13 Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
    Oct 17 Acrivon Therapeutics to Present Data Demonstrating Deployment of its AP3 Platform for Streamlined Drug Discovery and Clinical Development at Two Scientific Conferences - Human Proteome Organization World Congress and EORTC-NCI-AACR Symposium
    Oct 16 Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    Oct 12 Acrivon Therapeutics Launches Phase 1 Cancer Trial, Advances Oncology Pipeline
    Oct 11 Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity
    Sep 18 Breaking Down Acrivon: Deep Dive Into Revenue, Profitability, And Prospects
    Sep 14 Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis
    Sep 10 Acrivon Therapeutics to Present at the Cantor Global Healthcare Conference
    Sep 9 Acrivon Therapeutics to Host Virtual Investor Event to Review Positive Phase 2 Clinical Data of ACR-368 Presented at ESMO and Pipeline Progress, Including Clinical Candidate ACR-2316
    See more ACRV news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 11.9
    52 Week Low 3.19
    Average Volume 92,698
    200-Day Moving Average 7.36
    50-Day Moving Average 7.64
    20-Day Moving Average 7.82
    10-Day Moving Average 7.57
    Average True Range 0.46
    RSI (14) 32.43
    ADX 28.82
    +DI 16.13
    -DI 32.80
    Chandelier Exit (Long, 3 ATRs) 7.35
    Chandelier Exit (Short, 3 ATRs) 7.50
    Upper Bollinger Bands 9.21
    Lower Bollinger Band 6.44
    Percent B (%b) 0.02
    BandWidth 35.31
    MACD Line -0.28
    MACD Signal Line -0.05
    MACD Histogram -0.2331
    Fundamentals Value
    Market Cap 144.26 Million
    Num Shares 22.2 Million
    EPS -2.26
    Price-to-Earnings (P/E) Ratio -2.88
    Price-to-Sales 0.00
    Price-to-Book 0.57
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 7.00
    Resistance 3 (R3) 6.99 6.82 6.91
    Resistance 2 (R2) 6.82 6.69 6.82 6.88
    Resistance 1 (R1) 6.66 6.62 6.74 6.67 6.86
    Pivot Point 6.49 6.49 6.53 6.49 6.49
    Support 1 (S1) 6.33 6.36 6.41 6.34 6.14
    Support 2 (S2) 6.16 6.29 6.16 6.12
    Support 3 (S3) 6.00 6.16 6.09
    Support 4 (S4) 6.01